spec sheet6 rows
Metrifonate has one of the stranger backstories in Alzheimer's drug history; it started life decades earlier as an antischistosomal insecticide-derived organophosphate sold as Bilarcil, and only later did researchers realize its slow, pseudo-irreversible acetylcholinesterase inhibition made it a candidate for boosting acetylcholine in Alzheimer's disease. Bayer ran it through large placebo-controlled Phase III trials where it produced genuine, statistically significant cognitive improvement over placebo, real efficacy that few of its competitors in this archive ever achieved. Then, deep into trials, roughly twenty patients developed neuromuscular dysfunction and life-threatening respiratory paralysis, apparently related to how chronic organophosphate exposure sensitizes patients to subsequent anesthetic or neuromuscular-blocking agents; Bayer halted the program and withdrew its FDA application in 1997, turning a drug with real cognitive benefit into a cautionary tale about repurposing organophosphates for chronic dosing.
- significant cognitive improvement versus placebo in Phase III Alzheimer's trials, along with better clinical global impression and activities-of-daily-living scores
- long dosing interval due to its slow, pseudo-irreversible enzyme inhibition
- neuromuscular dysfunction and life-threatening respiratory failure reported in roughly 20 patients during extended trials, the reason development was halted
- peripheral cholinergic side effects typical of acetylcholinesterase inhibitors
- Metrifonate had already been used safely as an antiparasitic drug for decades under the name Bilarcil before anyone tested it for Alzheimer's disease, only for the switch to chronic daily dosing to reveal a serious neuromuscular risk that short-course antiparasitic use never had.
Mechanism
Organophosphate that spontaneously converts to dichlorvos in the body, which acts as a slow, pseudo-irreversible inhibitor of ; the long-lasting enzyme inhibition raises levels over an extended dosing interval.
Safetyrisks and cautions, not medical advice
In the trials themselves metrifonate looked mild. Six-month studies reported diarrhoea, nausea, leg cramps and a heart rate about nine beats per minute below placebo, with no liver signal and no muscle weakness. What ended it appeared only with extended dosing: roughly twenty patients developed neuromuscular dysfunction and life-threatening respiratory failure, and Bayer withdrew its FDA application in 1997. Metrifonate converts to dichlorvos and blocks acetylcholinesterase pseudo-irreversibly, so sustained organophosphate exposure sensitises people to neuromuscular blockers and anaesthesia.
History
Originally developed and marketed as the antischistosomal agent Bilarcil; repurposed by Bayer for Alzheimer's disease in the 1990s, reaching large Phase III trials that showed significant cognitive benefit before reports of respiratory paralysis in roughly 20 patients led Bayer to halt trials and withdraw its FDA application in 1997.
Subjective profileweighing the evidence above
One of the few compounds here that actually showed real efficacy in humans, undone by a safety signal serious enough to end the program outright.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Why is an anti-parasite drug relevant to Alzheimer's disease?
Metrifonate was originally developed to treat schistosomiasis; researchers later recognized that its slow-acting organophosphate mechanism inhibited acetylcholinesterase in a way that could be repurposed to raise brain acetylcholine levels in Alzheimer's disease.
Did metrifonate actually work for Alzheimer's before it was pulled?
Yes; Phase III trials showed statistically significant cognitive improvement over placebo, which makes its withdrawal, driven by rare but severe respiratory paralysis, a genuine loss rather than a simple failed-efficacy story.
Adverse effects
- neuromuscular dysfunction and life-threatening respiratory failure reported in roughly 20 patients during extended trials, the reason development was halted
- peripheral cholinergic side effects typical of acetylcholinesterase inhibitors